{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T23:53:56Z","timestamp":1793058836748,"version":"4.5.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Foundation Alzheimer Young Researcher Program","award":["1310194"],"award-info":[{"award-number":["1310194"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s00415-026-13760-x","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T16:14:20Z","timestamp":1774282460000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Eligibility for lecanemab treatment in a French memory clinic setting"],"prefix":"10.1007","volume":"273","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0761-7885","authenticated-orcid":false,"given":"Agathe","family":"Vrillon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl","family":"G\u00f6tze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Dumurgier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Cognat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Hourr\u00e8gue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esteban","family":"Munoz-Musat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Th\u00e9odore","family":"Decaix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Hugon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janina","family":"Estrada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Sebbagh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c9lodie","family":"Bouaziz-Amar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthieu","family":"Lilamand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Paquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,23]]},"reference":[{"issue":"1","key":"13760_CR1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M et al (2023) Lecanemab in early Alzheimer\u2019s disease. N Engl J Med 388(1):9\u201321. https:\/\/doi.org\/10.1056\/NEJMoa2212948. (PubMed PMID: 36449413.)","journal-title":"N Engl J Med"},{"issue":"6","key":"13760_CR2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J et al (2023) Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA 330(6):512. https:\/\/doi.org\/10.1001\/jama.2023.13239","journal-title":"JAMA"},{"issue":"2","key":"13760_CR3","doi-asserted-by":"publisher","first-page":"197","DOI":"10.14283\/jpad.2022.30","volume":"9","author":"S Budd Haeberlein","year":"2022","unstructured":"Budd Haeberlein S, Aisen PS, Barkhof F, Chalkias S, Chen T, Cohen S et al (2022) Two randomized phase 3 studies of aducanumab in early Alzheimer\u2019s disease. J Prev Alzheimers Dis 9(2):197\u2013210. https:\/\/doi.org\/10.14283\/jpad.2022.30. (PubMed PMID: 35542991.)","journal-title":"J Prev Alzheimers Dis"},{"issue":"12","key":"13760_CR4","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70905","volume":"21","author":"CH van Dyck","year":"2025","unstructured":"van Dyck CH, Sperling R, Johnson K, Dhadda S, Kanekiyo M, Li D et al (2025) Long-term safety and efficacy of lecanemab in early Alzheimer\u2019s disease: results from the Clarity AD open-label extension study. Alzheimers Dement 21(12):e70905. https:\/\/doi.org\/10.1002\/alz.70905. (PubMed PMID: 41355080; PubMed Central PMCID: PMC12682705.)","journal-title":"Alzheimers Dement"},{"key":"13760_CR5","unstructured":"Eisai Co., Ltd. FDA grants accelerated approval for Alzheimer\u2019s disease treatment lecanemab (Brand Name: LEQEMBITM) [Internet]. Available from https:\/\/www.eisai.com\/news\/2023\/news202301.html. 2023 Jan 6."},{"key":"13760_CR6","unstructured":"FDA. FDA approves treatment for adults with Alzheimer\u2019s disease [Internet]. 2023. Available from: https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-treatment-adults-alzheimers-disease"},{"key":"13760_CR7","unstructured":"European Medicines Agency. Leqembi Recommended for Treatment of Early Alzheimer\u2019s Disease. European Medicines Agency [Internet]. 2024. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/leqembi"},{"key":"13760_CR8","unstructured":"European Medicines Agency. Kinsula Recommended for treatment of early Alzheimer\u2019s disease [Internet]. 2025. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/kisunla"},{"issue":"1","key":"13760_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-025-01766-y","volume":"17","author":"KS Frederiksen","year":"2025","unstructured":"Frederiksen KS, Boada M, Dubois B, Engelborghs S, Frisoni GB, Georges J et al (2025) Navigating the introduction of anti-amyloid therapy in Europe: a position statement by individual members of the EADC. Alzheimers Res Ther 17(1):116. https:\/\/doi.org\/10.1186\/s13195-025-01766-y. (PubMed PMID: 40413561; PubMed Central PMCID: PMC12102950.)","journal-title":"Alzheimers Res Ther"},{"issue":"2","key":"13760_CR10","doi-asserted-by":"publisher","first-page":"265","DOI":"10.14283\/jpad.2024.37","volume":"11","author":"AC Bradshaw","year":"2024","unstructured":"Bradshaw AC, Georges J (2024) Anti-amyloid therapies for Alzheimer\u2019s disease: an Alzheimer Europe position paper and call to action. J Prev Alzheimers Dis 11(2):265\u2013273. https:\/\/doi.org\/10.14283\/jpad.2024.37. (PubMed PMID: 38374732.)","journal-title":"J Prev Alzheimers Dis"},{"issue":"11","key":"13760_CR11","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70875","volume":"21","author":"SY Jeon","year":"2025","unstructured":"Jeon SY, Byun MS, Choi HJ, Kim YH, Gwag CH, Oh Y et al (2025) Eligibility for lecanemab and donanemab in Korea under appropriate use recommendations. Alzheimers Dement 21(11):e70875. https:\/\/doi.org\/10.1002\/alz.70875. (PubMed PMID: 41225766; PubMed Central PMCID: PMC12611877.)","journal-title":"Alzheimers Dement"},{"issue":"6","key":"13760_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70375","volume":"21","author":"S Vigneswaran","year":"2025","unstructured":"Vigneswaran S, Vijverberg EGB, Barkhof F, Van De Giessen E, Lemstra AW, Pijnenburg Y et al (2025) \u201cReal\u2010world\u201d eligibility for anti\u2010amyloid treatment in a tertiary memory clinic setting. Alzheimers Dement 21(6):e70375. https:\/\/doi.org\/10.1002\/alz.70375","journal-title":"Alzheimers Dement"},{"issue":"5","key":"13760_CR13","doi-asserted-by":"publisher","DOI":"10.1192\/bjo.2024.747","volume":"10","author":"M Defrancesco","year":"2024","unstructured":"Defrancesco M, Gizewski ER, Mangesius S, Galijasevic M, Virgolini I, Kroiss A et al (2024) Investigating patient eligibility for anti-amyloid monoclonal antibody treatment of Alzheimer\u2019s disease: real-world data from an Austrian psychiatric memory clinic population. BJPsych Open 10(5):e160. https:\/\/doi.org\/10.1192\/bjo.2024.747. (PubMed PMID: 39308280; PubMed Central PMCID: PMC11457211.)","journal-title":"BJPsych Open"},{"issue":"10","key":"13760_CR14","doi-asserted-by":"publisher","first-page":"2995","DOI":"10.1111\/jgs.17390","volume":"69","author":"M Canevelli","year":"2021","unstructured":"Canevelli M, Rossi PD, Astrone P, Consorti E, Vanacore N, Cesari M (2021) \u201cReal world\u201d eligibility for aducanumab. J Am Geriatr Soc 69(10):2995\u20132998. https:\/\/doi.org\/10.1111\/jgs.17390","journal-title":"J Am Geriatr Soc"},{"issue":"4","key":"13760_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjpad.2025.100102","volume":"12","author":"J Rosen","year":"2025","unstructured":"Rosen J, Jessen F (2025) Patient eligibility for amyloid-targeting immunotherapies in Alzheimer\u2019s disease. J Prev Alzheimers Dis 12(4):100102. https:\/\/doi.org\/10.1016\/j.tjpad.2025.100102. (PubMed PMID: 40011174)","journal-title":"J Prev Alzheimers Dis"},{"issue":"19","key":"13760_CR16","doi-asserted-by":"publisher","first-page":"e2102","DOI":"10.1212\/WNL.0000000000201043","volume":"99","author":"A Rosenberg","year":"2022","unstructured":"Rosenberg A, \u00d6hlund-Wistbacka U, Hall A, Bonnard A, Hagman G, Ryd\u00e9n M et al (2022) \u03b2-Amyloid, Tau, neurodegeneration classification and eligibility for anti-amyloid treatment in a memory clinic population. Neurology 99(19):e2102\u2013e2113. https:\/\/doi.org\/10.1212\/WNL.0000000000201043. (PubMed PMID: 36130840; PubMed Central PMCID: PMC9651451)","journal-title":"Neurology"},{"issue":"6","key":"13760_CR17","doi-asserted-by":"publisher","first-page":"4331","DOI":"10.1002\/alz.13785","volume":"20","author":"JE Galvin","year":"2024","unstructured":"Galvin JE, Cummings JL, Benea ML, de Moor C, Allegri RF, Atri A et al (2024) Generating real-world evidence in Alzheimer\u2019s disease: considerations for establishing a core dataset. Alzheimers Dement 20(6):4331\u20134341. https:\/\/doi.org\/10.1002\/alz.13785. (PubMed PMID: 38706421; PubMed Central PMCID: PMC11180865)","journal-title":"Alzheimers Dement"},{"issue":"3","key":"13760_CR18","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1684\/pnv.2024.1186","volume":"22","author":"M Ceccaldi","year":"2024","unstructured":"Ceccaldi M, Monteil-Hautin V, Chevrette A, Lebouvier T, Lefran\u00e7ois M, Wallon D et al (2024) Overview of the French Memory Centres healthcare pathway for patients with early Alzheimer disease. Geriatr Psychol Neuropsychiatr Vieil 22(3):372\u2013379. https:\/\/doi.org\/10.1684\/pnv.2024.1186. (PubMed PMID: 39840421)","journal-title":"Geriatr Psychol Neuropsychiatr Vieil"},{"issue":"3","key":"13760_CR19","doi-asserted-by":"publisher","first-page":"362","DOI":"10.14283\/jpad.2023.30","volume":"10","author":"J Cummings","year":"2023","unstructured":"Cummings J, Apostolova L, Rabinovici GD, Atri A, Aisen P, Greenberg S et al (2023) Lecanemab: appropriate use recommendations. J Prev Alzheimers Dis 10(3):362\u2013377. https:\/\/doi.org\/10.14283\/jpad.2023.30. (PubMed PMID: 37357276; PubMed Central PMCID: PMC10313141)","journal-title":"J Prev Alzheimers Dis"},{"issue":"5","key":"13760_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjpad.2025.100150","volume":"12","author":"GD Rabinovici","year":"2025","unstructured":"Rabinovici GD, Selkoe DJ, Schindler SE, Aisen P, Apostolova LG, Atri A et al (2025) Donanemab: appropriate use recommendations. J Prev Alzheimers Dis 12(5):100150. https:\/\/doi.org\/10.1016\/j.tjpad.2025.100150. (PubMed PMID: 40155270)","journal-title":"J Prev Alzheimers Dis"},{"issue":"7","key":"13760_CR21","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1001\/jamaneurol.2025.1232","volume":"82","author":"M Paczynski","year":"2025","unstructured":"Paczynski M, Hofmann A, Posey Z, Gregersen M, Rudman M, Ellington D et al (2025) Lecanemab treatment in a specialty memory clinic. JAMA Neurol 82(7):655. https:\/\/doi.org\/10.1001\/jamaneurol.2025.1232","journal-title":"JAMA Neurol"},{"issue":"3","key":"13760_CR22","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1007\/s40120-025-00756-4","volume":"14","author":"MN Sabbagh","year":"2025","unstructured":"Sabbagh MN, Zhao C, Mahendran M, Jang SR, Lalibert\u00e9 F, Toyosaki H et al (2025) Characterizing the journey of early Alzheimer\u2019s disease in patients initiating lecanemab treatment in the United States: a real-world evidence study. Neurol Ther 14(3):1115\u20131127. https:\/\/doi.org\/10.1007\/s40120-025-00756-4. (PubMed PMID: 40319433; PubMed Central PMCID: PMC12089008)","journal-title":"Neurol Ther"},{"issue":"1","key":"13760_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-025-01763-1","volume":"17","author":"N Bregman","year":"2025","unstructured":"Bregman N, Nathan T, Shir D, Omer N, Levy MH, David AB et al (2025) Lecanemab in clinical practice: real-world outcomes in early Alzheimer\u2019s disease. Alzheimers Res Ther 17(1):119. https:\/\/doi.org\/10.1186\/s13195-025-01763-1","journal-title":"Alzheimers Res Ther"},{"key":"13760_CR24","doi-asserted-by":"publisher","DOI":"10.1177\/13872877251406619","author":"L Leng","year":"2025","unstructured":"Leng L, Liao Z, Lu P, Sun Y, Weng Q, Fan W et al (2025) Real-world experience with baseline characteristics and safety of lecanemab for Alzheimer\u2019s disease in Eastern China. J Alzheimers Dis. https:\/\/doi.org\/10.1177\/13872877251406619","journal-title":"J Alzheimers Dis"},{"issue":"4","key":"13760_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjpad.2025.100094","volume":"12","author":"N Villain","year":"2025","unstructured":"Villain N, Planche V, Lilamand M, Cordonnier C, Soto-Martin M, Mollion H et al (2025) Lecanemab for early Alzheimer\u2019s disease: appropriate use recommendations from the French federation of memory clinics. J Prevent Alzheimer\u2019s Dis 12(4):100094. https:\/\/doi.org\/10.1016\/j.tjpad.2025.100094","journal-title":"J Prevent Alzheimer's Dis"},{"issue":"8","key":"13760_CR26","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1002\/alz.13859","volume":"20","author":"CR Jack","year":"2024","unstructured":"Jack CR, Andrews JS, Beach TG, Buracchio T, Dunn B, Graf A et al (2024) Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s Association Workgroup. Alzheimers Dement 20(8):5143\u20135169. https:\/\/doi.org\/10.1002\/alz.13859","journal-title":"Alzheimers Dement"},{"issue":"6","key":"13760_CR27","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1007\/s00415-014-7335-6","volume":"261","author":"J Dumurgier","year":"2014","unstructured":"Dumurgier J, Laplanche JL, Mouton-Liger F, Lapalus P, Indart S, Pr\u00e9vot M et al (2014) The screening of Alzheimer\u2019s patients with CSF biomarkers, modulates the distribution of APOE genotype: impact on clinical trials. J Neurol 261(6):1187\u20131195. https:\/\/doi.org\/10.1007\/s00415-014-7335-6","journal-title":"J Neurol"},{"issue":"4","key":"13760_CR28","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1002\/alz.12406","volume":"18","author":"AC Van Harten","year":"2022","unstructured":"Van Harten AC, Wiste HJ, Weigand SD, Mielke MM, Kremers WK, Eichenlaub U et al (2022) Detection of Alzheimer\u2019s disease amyloid beta 1\u201042, p\u2010tau, and t\u2010tau assays. Alzheimers Dement 18(4):635\u2013644. https:\/\/doi.org\/10.1002\/alz.12406","journal-title":"Alzheimers Dement"},{"issue":"4","key":"13760_CR29","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack","year":"2018","unstructured":"Jack CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB et al (2018) NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement 14(4):535\u2013562. https:\/\/doi.org\/10.1016\/j.jalz.2018.02.018","journal-title":"Alzheimers Dement"},{"issue":"11","key":"13760_CR30","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1111\/j.1532-5415.1992.tb01802.x","volume":"40","author":"P Barberger-Gateau","year":"1992","unstructured":"Barberger-Gateau P, Commenges D, Gagnon M, Letenneur L, Sauvel C, Dartigues JF (1992) Instrumental activities of daily living as a screening tool for cognitive impairment and dementia in elderly community dwellers. J Am Geriatr Soc 40(11):1129\u20131134. https:\/\/doi.org\/10.1111\/j.1532-5415.1992.tb01802.x","journal-title":"J Am Geriatr Soc"},{"issue":"2","key":"13760_CR31","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1111\/jgs.17530","volume":"70","author":"A Padovani","year":"2022","unstructured":"Padovani A, Caratozzolo S, Rozzini L, Pilotto A, Benussi A, Tedeschi G (2022) \u201cReal-world\u201d eligibility for aducanumab depends on clinical setting and patients\u2019 journey. J Am Geriatr Soc 70(2):626\u2013628. https:\/\/doi.org\/10.1111\/jgs.17530","journal-title":"J Am Geriatr Soc"},{"issue":"3","key":"13760_CR32","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s10654-025-01220-1","volume":"40","author":"JJ Claus","year":"2025","unstructured":"Claus JJ, Vom Hofe I, van Ijlzinga Veenstra A, Licher S, Seelaar H, de Jong FJ et al (2025) Generalizability of trial criteria on amyloid-lowering therapy against Alzheimer\u2019s disease to individuals with mild cognitive impairment or early Alzheimer\u2019s disease in the general population. Eur J Epidemiol 40(3):327\u2013337. https:\/\/doi.org\/10.1007\/s10654-025-01220-1","journal-title":"Eur J Epidemiol"},{"key":"13760_CR33","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000207770","author":"RR Pittock","year":"2023","unstructured":"Pittock RR, Aakre JA, Castillo AM, Ramanan VK, Kremers WK, Jack CR et al (2023) Eligibility for anti-amyloid treatment in a population-based study of cognitive aging. Neurology. https:\/\/doi.org\/10.1212\/WNL.0000000000207770","journal-title":"Neurology"},{"issue":"6","key":"13760_CR34","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1192\/bjp.2023.166","volume":"224","author":"AAS Laurell","year":"2024","unstructured":"Laurell AAS, Venkataraman AV, Schmidt T, Montagnese M, Mueller C, Stewart R et al (2024) Estimating demand for potential disease-modifying therapies for Alzheimer\u2019s disease in the UK. Br J Psychiatry 224(6):198\u2013204. https:\/\/doi.org\/10.1192\/bjp.2023.166","journal-title":"Br J Psychiatry"},{"issue":"11","key":"13760_CR35","doi-asserted-by":"publisher","first-page":"e1137","DOI":"10.1212\/WNL.0000000000200040","volume":"98","author":"N Mattsson-Carlgren","year":"2022","unstructured":"Mattsson-Carlgren N, Grinberg LT, Boxer A, Ossenkoppele R, Jonsson M, Seeley W et al (2022) Cerebrospinal fluid biomarkers in autopsy-confirmed Alzheimer disease and frontotemporal lobar degeneration. Neurology 98(11):e1137\u2013e1150. https:\/\/doi.org\/10.1212\/WNL.0000000000200040","journal-title":"Neurology"},{"issue":"3","key":"13760_CR36","first-page":"2","volume":"8","author":"JP Hlavka","year":"2019","unstructured":"Hlavka JP, Mattke S, Liu JL (2019) Assessing the preparedness of the health care system infrastructure in six European Countries for an Alzheimer\u2019s treatment. Rand Health Quarterly 8(3):2","journal-title":"Rand Health Quarterly"},{"key":"13760_CR37","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.70102","author":"S Nakashima","year":"2025","unstructured":"Nakashima S, Sato K, Niimi Y, Ihara R, Suzuki K, Iwata A et al (2025) Therapeutic time window of disease\u2010modifying therapy for early Alzheimer\u2019s disease. Alzheimers Dement N Y. https:\/\/doi.org\/10.1002\/trc2.70102","journal-title":"Alzheimers Dement N Y"},{"issue":"1","key":"13760_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-024-01521-9","volume":"16","author":"MD Howe","year":"2024","unstructured":"Howe MD, Britton KJ, Joyce HE, Menard W, Emrani S, Kunicki ZJ et al (2024) Clinical application of plasma P-tau217 to assess eligibility for amyloid-lowering immunotherapy in memory clinic patients with early Alzheimer\u2019s disease. Alzheimers Res Ther 16(1):154. https:\/\/doi.org\/10.1186\/s13195-024-01521-9","journal-title":"Alzheimers Res Ther"},{"issue":"11","key":"13760_CR39","doi-asserted-by":"publisher","first-page":"4414","DOI":"10.1093\/brain\/awad188","volume":"146","author":"H Hampel","year":"2023","unstructured":"Hampel H, Elhage A, Cho M, Apostolova LG, Nicoll JAR, Atri A (2023) Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics. Brain 146(11):4414\u20134424. https:\/\/doi.org\/10.1093\/brain\/awad188","journal-title":"Brain"},{"issue":"5","key":"13760_CR40","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2025.0065","volume":"82","author":"JA Zimmer","year":"2025","unstructured":"Zimmer JA, Ardayfio P, Wang H, Khanna R, Evans CD, Lu M et al (2025) Amyloid-related imaging abnormalities with Donanemab in early symptomatic Alzheimer Disease: secondary analysis of the TRAILBLAZER-ALZ and ALZ 2 randomized clinical trials. JAMA Neurol 82(5):461. https:\/\/doi.org\/10.1001\/jamaneurol.2025.0065","journal-title":"JAMA Neurol"},{"key":"13760_CR41","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2024.1326784","volume":"18","author":"SJ Doran","year":"2024","unstructured":"Doran SJ, Sawyer RP (2024) Risk factors in developing amyloid related imaging abnormalities (ARIA) and clinical implications. Front Neurosci 18:1326784. https:\/\/doi.org\/10.3389\/fnins.2024.1326784","journal-title":"Front Neurosci"},{"issue":"10","key":"13760_CR42","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1161\/STROKEAHA.113.002267","volume":"44","author":"AL Cheng","year":"2013","unstructured":"Cheng AL, Batool S, McCreary CR, Lauzon ML, Frayne R, Goyal M et al (2013) Susceptibility-weighted imaging is more reliable than T2*-weighted gradient-recalled echo MRI for detecting microbleeds. Stroke 44(10):2782\u20132786. https:\/\/doi.org\/10.1161\/STROKEAHA.113.002267","journal-title":"Stroke"},{"issue":"6","key":"13760_CR43","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.3174\/ajnr.A4248","volume":"36","author":"S Shams","year":"2015","unstructured":"Shams S, Martola J, Cavallin L, Granberg T, Shams M, Aspelin P et al (2015) SWI or T2*: which MRI sequence to use in the detection of cerebral microbleeds? The Karolinska imaging dementia study. AJNR Am J Neuroradiol 36(6):1089\u20131095. https:\/\/doi.org\/10.3174\/ajnr.A4248","journal-title":"AJNR Am J Neuroradiol"},{"issue":"5","key":"13760_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2025.100695","volume":"6","author":"H Hampel","year":"2025","unstructured":"Hampel H, Li G, Mielke MM, Galvin JE, Kivipelto M, Santarnecchi E et al (2025) The impact of real-world evidence in implementing and optimizing Alzheimer\u2019s disease care. Med 6(5):100695. https:\/\/doi.org\/10.1016\/j.medj.2025.100695","journal-title":"Med"},{"issue":"12","key":"13760_CR45","doi-asserted-by":"publisher","first-page":"6875","DOI":"10.1007\/s10072-025-08576-y","volume":"46","author":"A Benussi","year":"2025","unstructured":"Benussi A, Agosta F, Alfano AR, Antico A, Bellelli G, Bonanni L et al (2025) Italian intersocietal recommendations for restructuring the diagnostic-therapeutic pathway for the implementation and appropriate use of anti-amyloid monoclonal antibodies in Alzheimer\u2019s disease. Neurol Sci 46(12):6875\u20136894. https:\/\/doi.org\/10.1007\/s10072-025-08576-y","journal-title":"Neurol Sci"},{"issue":"10","key":"13760_CR46","doi-asserted-by":"publisher","first-page":"3509","DOI":"10.1007\/s10072-023-06885-8","volume":"44","author":"G Bellelli","year":"2023","unstructured":"Bellelli G, Zucchelli A, Benussi A, Pinardi E, Caratozzolo S, Ornago AM et al (2023) Assessing frailty at the centers for dementia and cognitive decline in Italy: potential implications for improving care of older people living with dementia. Neurol Sci 44(10):3509\u20133514. https:\/\/doi.org\/10.1007\/s10072-023-06885-8","journal-title":"Neurol Sci"},{"issue":"7","key":"13760_CR47","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1002\/alz.12285","volume":"17","author":"M Rahman","year":"2021","unstructured":"Rahman M, White EM, Mills C, Thomas KS, Jutkowitz E (2021) Rural-urban differences in diagnostic incidence and prevalence of Alzheimer\u2019s disease and related dementias. Alzheimers Dement 17(7):1213\u20131230. https:\/\/doi.org\/10.1002\/alz.12285","journal-title":"Alzheimers Dement"},{"issue":"4","key":"13760_CR48","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1017\/cjn.2023.270","volume":"51","author":"SE Black","year":"2024","unstructured":"Black SE, Budd N, Nygaard HB, Verret L, Virdi S, Tamblyn Watts L et al (2024) A model predicting healthcare capacity gaps for Alzheimer\u2019s disease-modifying treatment in Canada. Can J Neurol Sci 51(4):487\u2013494. https:\/\/doi.org\/10.1017\/cjn.2023.270. (PubMed PMID: 37593895.)","journal-title":"Can J Neurol Sci"},{"key":"13760_CR49","doi-asserted-by":"publisher","DOI":"10.1177\/25424823251370708","volume":"9","author":"CS Casey","year":"2025","unstructured":"Casey CS, Patel N, Vasileva-Metodiev SZ, Cotton S, Walker C, Nilforooshan R (2025) Real-world diagnosis and management of mild cognitive impairment and Alzheimer\u2019s disease dementia in the United Kingdom. J Alzheimers Dis Rep 9:25424823251370708. https:\/\/doi.org\/10.1177\/25424823251370708. (PubMed PMID: 41122344; PubMed Central PMCID: PMC12536203.)","journal-title":"J Alzheimers Dis Rep"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-13760-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-026-13760-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-13760-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T01:48:30Z","timestamp":1776649710000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-026-13760-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,23]]},"references-count":49,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["13760"],"URL":"https:\/\/doi.org\/10.1007\/s00415-026-13760-x","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,23]]},"assertion":[{"value":"9 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AV, KG, EC, CH, EMM, TD, JE, MS, and EBA declare no disclosures related to this study. JH declares consultant fees for Roche SAS and Eisai SAS. JD declares consultant fees from Eli Lilly, Lilly France, Roche Diagnostics International LTD, Eisai SAS, and Novo Nordisk. ML declares being an investigator or co-investigator for studies by Bayer and Bristol-Myers Squibb laboratories (unpaid), participation in the Eisai Symposium on Behavioural Neurology 2023 (unpaid), and consulting for a brochure on Alzheimer's disease Eisai 2024 (paid). CP declares consulting fees from Eli Lilly, Roche, and Eisai (all paid to the institution); payment or honoraria from Fondation Assistance Publique \u2013 H\u00f4pitaux de Paris for a presentation; participation on a data safety monitoring boards or advisory boards for Eli Lilly, Roche, and Eisai; a leadership or fiduciary role in Fondation Vaincre Alzheimer, Association Maladie \u00e0 corps de Lewy, and France Alzheimer.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"All patients provided oral and written informed consent for participation in the BioCogBank study, a prospective clinical study of neurocognitive disorders and biomarkers (NCT06244875). The BioCogBank study was approved by the ethics committee Comit\u00e9 de Protection des Personnes Est III (2023-A01413-42, 23\u201310-02) and was conducted in accordance with the principles of the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"228"}}